Towards defining biomarkers indicating resistances to targeted therapies

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 5, 2014, Pages 909-916

  Stehle, Franziska ^a   Schulz, Kristin ^a   Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Proteomics; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; INTERLEUKIN 6; NILOTINIB; PANITUMUMAB; PAZOPANIB; PROTEOME; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN GENOME; ISOTOPE LABELING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVIEW; TUMOR MICROENVIRONMENT;

PROTEOMICS; TARGETED THERAPY; TYROSINE KINASE INHIBITOR;

DRUG RESISTANCE, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898602164     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2013.11.006     Document Type: Review

References (104)

1. B.D. Manning Challenges and opportunities in defining the essential cancer kinome Sci. Signal. 2 2009 pe15
2. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
3. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
4. G. Giamas, Y.L. Man, H. Hirner, J. Bischof, K. Kramer, K. Khan, S.S. Ahmed, J. Stebbing, and U. Knippschild Kinases as targets in the treatment of solid tumors Cell. Signal. 22 2010 984 1002
5. D. Gonzalez de Castro, P.A. Clarke, B. Al-Lazikani, and P. Workman Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance Clin. Pharmacol. Ther. 93 2013 252 259
6. J. Baselga Targeting tyrosine kinases in cancer: the second wave Science 312 2006 1175 1178 (Pubitemid 43801135)
7. J. Baselga, J. Albanell, M.A. Molina, and J. Arribas Mechanism of action of trastuzumab and scientific update Semin. Oncol. 28 2001 4 11 (Pubitemid 33065104)
8. J. Albanell, and J. Baselga Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect J. Natl. Cancer Inst. 93 2001 1830 1832 (Pubitemid 34048643)
9. M. Benekli, H. Baumann, and M. Wetzler Targeting signal transducer and activator of transcription signaling pathway in leukemias J. Clin. Oncol. 27 2009 4422 4432
10. B.J. Druker Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML Oncogene 21 2002 8541 8546 (Pubitemid 36084186)
11. J. Rinehart, A.A. Adjei, P.M. Lorusso, D. Waterhouse, J.R. Hecht, R.B. Natale, O. Hamid, M. Varterasian, P. Asbury, E.P. Kaldjian, S. Gulyas, D.Y. Mitchell, R. Herrera, J.S. Sebolt-Leopold, and M.B. Meyer Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J. Clin. Oncol. 22 2004 4456 4462 (Pubitemid 41185111)
12. Z.Z. Lin, H.C. Hsu, C.H. Hsu, P.Y. Yeh, C.Y. Huang, Y.F. Huang, T.J. Chen, S.H. Kuo, C. Hsu, F.C. Hu, Y.M. Jeng, Y. Chung, and A.L. Cheng The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma J. Hepatol. 50 2009 518 527
13. M. Dammann, and F. Weber Personalized medicine: caught between hope, hype and the real world Clinics (Sao Paulo) 67 Suppl. 1 2012 91 97
14. A. Sartore-Bianchi, M. Delorenzi, T. Gagnon-Kugler, C. Rousseau, and G. Batist New frontiers in therapeutic resistance in cancer Expert. Rev. Anticancer. Ther. 12 2012 877 879
15. J.L. Gonzalez Larriba, E. Espinosa, I. Garcia Carbonero, J. Garcia-Donas, M. Lopez, A. Meana, J. Puente, and J. Bellmunt Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action Cancer Metastasis Rev. 31 Suppl. 1 2012 S11 S17
16. B.P. Rubin, and A. Duensing Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors Lab. Invest. 86 2006 981 986 (Pubitemid 44423063)
17. F. Shojaei, X. Wu, A.K. Malik, C. Zhong, M.E. Baldwin, S. Schanz, G. Fuh, H.P. Gerber, and N. Ferrara Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Nat. Biotechnol. 25 2007 911 920 (Pubitemid 47236916)
18. J.C. Welti, M. Gourlaouen, T. Powles, S.C. Kudahetti, P. Wilson, D.M. Berney, and A.R. Reynolds Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib Oncogene 30 2011 1183 1193
19. N. Ferrara Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis Curr. Opin. Hematol. 17 2010 219 224
20. J.S. Carew, K.R. Kelly, and S.T. Nawrocki Mechanisms of mTOR inhibitor resistance in cancer therapy Target. Oncol. 6 2011 17 27
21. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 8 2008 592 603
22. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309 (Pubitemid 41443415)
23. R.S. Bhatt, X. Wang, L. Zhang, M.P. Collins, S. Signoretti, D.C. Alsop, S.N. Goldberg, M.B. Atkins, and J.W. Mier Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling Mol. Cancer Ther. 9 2010 2793 2802
24. H.J. Hammers, H.M. Verheul, B. Salumbides, R. Sharma, M. Rudek, J. Jaspers, P. Shah, L. Ellis, L. Shen, S. Paesante, K. Dykema, K. Furge, B.T. Teh, G. Netto, and R. Pili Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Mol. Cancer Ther. 9 2010 1525 1535
25. D. Huang, Y. Ding, M. Zhou, B.I. Rini, D. Petillo, C.N. Qian, R. Kahnoski, P.A. Futreal, K.A. Furge, and B.T. Teh Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Cancer Res. 70 2010 1063 1071
26. B.I. Rini, and M.B. Atkins Resistance to targeted therapy in renal-cell carcinoma Lancet Oncol. 10 2009 992 1000
27. S.M. Graham, H.G. Jorgensen, E. Allan, C. Pearson, M.J. Alcorn, L. Richmond, and T.L. Holyoake Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 2002 319 325
28. M. Copland, A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, N. Jordanides, M. Barow, J.C. Mountford, and T.L. Holyoake Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood 107 2006 4532 4539 (Pubitemid 43801382)
29. P. le Coutre, E. Tassi, M. Varella-Garcia, R. Barni, L. Mologni, G. Cabrita, E. Marchesi, R. Supino, and C. Gambacorti-Passerini Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 95 2000 1758 1766 (Pubitemid 30120840)
30. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, and P.A. Janne MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
31. L.M. Ellis, and D.J. Hicklin Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology Clin. Cancer Res. 15 2009 7471 7478
32. K.W. Cheng, C.C. Wong, M. Wang, Q.Y. He, and F. Chen Identification and characterization of molecular targets of natural products by mass spectrometry Mass Spectrom. Rev. 29 2010 126 155
33. W. Kolch, and A. Pitt Functional proteomics to dissect tyrosine kinase signalling pathways in cancer Nat. Rev. Cancer 10 2010 618 629
34. M. Bantscheff, A. Scholten, and A.J. Heck Revealing promiscuous drug-target interactions by chemical proteomics Drug Discov. Today 14 2009 1021 1029
35. M. Unlu, M.E. Morgan, and J.S. Minden Difference gel electrophoresis: a single gel method for detecting changes in protein extracts Electrophoresis 18 1997 2071 2077 (Pubitemid 27501267)
36. B. Seliger, S.P. Dressler, E. Wang, R. Kellner, C.V. Recktenwald, F. Lottspeich, F.M. Marincola, M. Baumgartner, D. Atkins, and R. Lichtenfels Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma Proteomics 9 2009 1567 1581
37. B. Seliger, S.P. Dressler, R. Lichtenfels, and R. Kellner Candidate biomarkers in renal cell carcinoma Proteomics 7 2007 4601 4612
38. S. Luhn, M. Berth, M. Hecker, and J. Bernhardt Using standard positions and image fusion to create proteome maps from collections of two-dimensional gel electrophoresis images Proteomics 3 2003 1117 1127 (Pubitemid 36929534)
39. M. Berth, F.M. Moser, M. Kolbe, and J. Bernhardt The state of the art in the analysis of two-dimensional gel electrophoresis images Appl. Microbiol. Biotechnol. 76 2007 1223 1243 (Pubitemid 47459790)
40. T.D. Veenstra Global and targeted quantitative proteomics for biomarker discovery J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 847 2007 3 11 (Pubitemid 46216196)
41. A. Stalmach, A. Albalat, W. Mullen, and H. Mischak Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications Electrophoresis 34 2013 1452 1464
42. A. Latosinska, M. Frantzi, A. Vlahou, and H. Mischak Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: focus on bladder cancer Proteomics Clin. Appl. 2013 10.1002/prca.201300038 (PMID:23970371) (Electronic publication ahead of print)
43. S.E. Ong, B. Blagoev, I. Kratchmarova, D.B. Kristensen, H. Steen, A. Pandey, and M. Mann Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics Mol. Cell. Proteomics 1 2002 376 386
44. S.P. Gygi, B. Rist, S.A. Gerber, F. Turecek, M.H. Gelb, and R. Aebersold Quantitative analysis of complex protein mixtures using isotope-coded affinity tags Nat. Biotechnol. 17 1999 994 999 (Pubitemid 29474856)
45. P.L. Ross, Y.N. Huang, J.N. Marchese, B. Williamson, K. Parker, S. Hattan, N. Khainovski, S. Pillai, S. Dey, S. Daniels, S. Purkayastha, P. Juhasz, S. Martin, M. Bartlet-Jones, F. He, A. Jacobson, and D.J. Pappin Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents Mol. Cell. Proteomics 3 2004 1154 1169
46. F. Lanucara, and C.E. Eyers Top-down mass spectrometry for the analysis of combinatorial post-translational modifications Mass Spectrom. Rev. 32 2013 27 42
47. J. Lee, S. Kim, P. Kim, X. Liu, T. Lee, K.M. Kim, I.G. Do, J.O. Park, S.H. Park, J. Jang, N. Hoe, G. Harvie, A. Kuller, A. Jain, G. Meyer, G. Leesman, Y.S. Park, M.G. Choi, T.S. Sohn, J.M. Bae, H.Y. Lim, S. Singh, and W.K. Kang A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers PLoS One 8 2013 e54644
48. N.L. Anderson, N.G. Anderson, T.W. Pearson, C.H. Borchers, A.G. Paulovich, S.D. Patterson, M. Gillette, R. Aebersold, and S.A. Carr A human proteome detection and quantitation project Mol. Cell. Proteomics 8 2009 883 886
49. A. Turtoi, E. De Pauw, and V. Castronovo Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies Am. J. Pathol. 178 2011 12 18
50. P.G. Righetti, E. Boschetti, L. Lomas, and A. Citterio Protein equalizer technology: the quest for a democratic proteome Proteomics 6 2006 3980 3992
51. M.R. Emmert-Buck, R.F. Bonner, P.D. Smith, R.F. Chuaqui, Z. Zhuang, S.R. Goldstein, R.A. Weiss, and L.A. Liotta Laser capture microdissection Science 274 1996 998 1001 (Pubitemid 26398425)
52. L.F. Waanders, K. Chwalek, M. Monetti, C. Kumar, E. Lammert, and M. Mann Quantitative proteomic analysis of single pancreatic islets Proc. Natl. Acad. Sci. U. S. A. 106 2009 18902 18907
53. N. Navin, A. Krasnitz, L. Rodgers, K. Cook, J. Meth, J. Kendall, M. Riggs, Y. Eberling, J. Troge, V. Grubor, D. Levy, P. Lundin, S. Maner, A. Zetterberg, J. Hicks, and M. Wigler Inferring tumor progression from genomic heterogeneity Genome Res. 20 2010 68 80
54. C. Ruiz, E. Lenkiewicz, L. Evers, T. Holley, A. Robeson, J. Kiefer, M.J. Demeure, M.A. Hollingsworth, M. Shen, D. Prunkard, P.S. Rabinovitch, T. Zellweger, S. Mousses, J.M. Trent, J.D. Carpten, L. Bubendorf, D. Von Hoff, and M.T. Barrett Advancing a clinically relevant perspective of the clonal nature of cancer Proc. Natl. Acad. Sci. U. S. A. 108 2011 12054 12059
55. J.M. Irish, R. Hovland, P.O. Krutzik, O.D. Perez, O. Bruserud, B.T. Gjertsen, and G.P. Nolan Single cell profiling of potentiated phospho-protein networks in cancer cells Cell 118 2004 217 228 (Pubitemid 38962577)
56. J.M. Irish, N. Kotecha, and G.P. Nolan Mapping normal and cancer cell signalling networks: towards single-cell proteomics Nat. Rev. Cancer 6 2006 146 155 (Pubitemid 43361547)
57. S. Hanash, and A. Taguchi The grand challenge to decipher the cancer proteome Nat. Rev. Cancer 10 2010 652 660
58. D.K. Nomura, M.M. Dix, and B.F. Cravatt Activity-based protein profiling for biochemical pathway discovery in cancer Nat. Rev. Cancer 10 2010 630 638
59. K. Ashman, and E.L. Villar Phosphoproteomics and cancer research Clin. Transl. Oncol. 11 2009 356 362
60. G.R. Oxnard, M.E. Arcila, J. Chmielecki, M. Ladanyi, V.A. Miller, and W. Pao New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer Clin. Cancer Res. 17 2011 5530 5537
61. R.K. Jain, D.G. Duda, C.G. Willett, D.V. Sahani, A.X. Zhu, J.S. Loeffler, T.T. Batchelor, and A.G. Sorensen Biomarkers of response and resistance to antiangiogenic therapy Nat. Rev. Clin. Oncol. 6 2009 327 338
62. S. Hoelder, P.A. Clarke, and P. Workman Discovery of small molecule cancer drugs: successes, challenges and opportunities Mol. Oncol. 6 2012 155 176
63. I. Collins, and P. Workman New approaches to molecular cancer therapeutics Nat. Chem. Biol. 2 2006 689 700 (Pubitemid 44764211)
64. C.N. Oldenhuis, S.F. Oosting, J.A. Gietema, and E.G. de Vries Prognostic versus predictive value of biomarkers in oncology Eur. J. Cancer 44 2008 946 953
65. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark REporting recommendations for tumor MARKer prognostic studies (REMARK) Nat. Clin. Pract. Oncol. 2 2005 416 422 (Pubitemid 43115010)
66. M. Peeters, T.J. Price, A. Cervantes, A.F. Sobrero, M. Ducreux, Y. Hotko, T. Andre, E. Chan, F. Lordick, C.J. Punt, A.H. Strickland, G. Wilson, T.E. Ciuleanu, L. Roman, E. Van Cutsem, V. Tzekova, S. Collins, K.S. Oliner, A. Rong, and J. Gansert Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J. Clin. Oncol. 28 2010 4706 4713
67. E. Van Cutsem, C.H. Kohne, I. Lang, G. Folprecht, M.P. Nowacki, S. Cascinu, I. Shchepotin, J. Maurel, D. Cunningham, S. Tejpar, M. Schlichting, A. Zubel, I. Celik, P. Rougier, and F. Ciardiello Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J. Clin. Oncol. 29 2011 2011 2019
68. M. Fukuoka, Y.L. Wu, S. Thongprasert, P. Sunpaweravong, S.S. Leong, V. Sriuranpong, T.Y. Chao, K. Nakagawa, D.T. Chu, N. Saijo, E.L. Duffield, Y. Rukazenkov, G. Speake, H. Jiang, A.A. Armour, K.F. To, J.C. Yang, and T.S. Mok Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J. Clin. Oncol. 29 2011 2866 2874
69. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J.J. Yang, B. Chewaskulyong, H. Jiang, E.L. Duffield, C.L. Watkins, A.A. Armour, and M. Fukuoka Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
70. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, R. Palmero, R. Garcia-Gomez, C. Pallares, J.M. Sanchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Moran, A. Insa, F. De Marinis, R. Corre, I. Bover, A. Illiano, E. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jimenez, M. Provencio, M.A. Moreno, J. Terrasa, J. Munoz-Langa, J. Valdivia, D. Isla, M. Domine, O. Molinier, J. Mazieres, N. Baize, R. Garcia-Campelo, G. Robinet, D. Rodriguez-Abreu, G. Lopez-Vivanco, V. Gebbia, L. Ferrera-Delgado, P. Bombaron, R. Bernabe, A. Bearz, A. Artal, E. Cortesi, C. Rolfo, M. Sanchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J.L. Ramirez, J.J. Sanchez, M.A. Molina, M. Taron, and L. Paz-Ares Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol. 13 2011 239 246
71. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, and G.A. McArthur Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
72. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C.U. Blank, W.H. Miller Jr., E. Kaempgen, S. Martin-Algarra, B. Karaszewska, C. Mauch, V. Chiarion-Sileni, A.M. Martin, S. Swann, P. Haney, B. Mirakhur, M.E. Guckert, V. Goodman, and P.B. Chapman Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
73. F. Gottardo, C.G. Liu, M. Ferracin, G.A. Calin, M. Fassan, P. Bassi, C. Sevignani, D. Byrne, M. Negrini, F. Pagano, L.G. Gomella, C.M. Croce, and R. Baffa Micro-RNA profiling in kidney and bladder cancers Urol. Oncol. 25 2007 387 392 (Pubitemid 47362758)
74. M. Jung, H.J. Mollenkopf, C. Grimm, I. Wagner, M. Albrecht, T. Waller, C. Pilarsky, M. Johannsen, C. Stephan, H. Lehrach, W. Nietfeld, T. Rudel, K. Jung, and G. Kristiansen MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy J. Cell. Mol. Med. 13 2009 3918 3928
75. J. Heinzelmann, B. Henning, J. Sanjmyatav, N. Posorski, T. Steiner, H. Wunderlich, M.R. Gajda, and K. Junker Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma World J. Urol. 29 2011 367 373
76. S. Flamant, W. Ritchie, J. Guilhot, J. Holst, M.L. Bonnet, J.C. Chomel, F. Guilhot, A.G. Turhan, and J.E. Rasko Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia Haematologica 95 2010 1325 1333
77. A. Gamez-Pozo, L.M. Anton-Aparicio, C. Bayona, P. Borrega, M.I. Gallegos Sancho, R. Garcia-Dominguez, T. de Portugal, M. Ramos-Vazquez, R. Perez-Carrion, M.V. Bolos, R. Madero, I. Sanchez-Navarro, J.A. Fresno Vara, and E. Espinosa Arranz MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients Neoplasia 14 2012 1144 1152
78. L. Rink, Y. Skorobogatko, A.V. Kossenkov, M.G. Belinsky, T. Pajak, M.C. Heinrich, C.D. Blanke, M. von Mehren, M.F. Ochs, B. Eisenberg, and A.K. Godwin Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor Mol. Cancer Ther. 8 2009 2172 2182
79. L. Rink, M.F. Ochs, Y. Zhou, M. von Mehren, and A.K. Godwin ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor PLoS One 8 2013 e54477
80. E.S. Boja, and H. Rodriguez The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science Korean J. Lab. Med. 31 2011 61 71
81. M. Bantscheff, D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, S. Hobson, T. Mathieson, J. Perrin, M. Raida, C. Rau, V. Reader, G. Sweetman, A. Bauer, T. Bouwmeester, C. Hopf, U. Kruse, G. Neubauer, N. Ramsden, J. Rick, B. Kuster, and G. Drewes Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25 2007 1035 1044 (Pubitemid 47517638)
82. U. Rix, O. Hantschel, G. Durnberger, L.L. Remsing Rix, M. Planyavsky, N.V. Fernbach, I. Kaupe, K.L. Bennett, P. Valent, J. Colinge, T. Kocher, and G. Superti-Furga Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 110 2007 4055 4063 (Pubitemid 350248462)
83. M. Brehme, O. Hantschel, J. Colinge, I. Kaupe, M. Planyavsky, T. Kocher, K. Mechtler, K.L. Bennett, and G. Superti-Furga Charting the molecular network of the drug target Bcr-Abl Proc. Natl. Acad. Sci. U. S. A. 106 2009 7414 7419
84. S. Balabanov, A. Gontarewicz, P. Ziegler, U. Hartmann, W. Kammer, M. Copland, U. Brassat, M. Priemer, I. Hauber, T. Wilhelm, G. Schwarz, L. Kanz, C. Bokemeyer, J. Hauber, T.L. Holyoake, A. Nordheim, and T.H. Brummendorf Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach Blood 109 2007 1701 1711 (Pubitemid 46239605)
85. C.G. Willett, D.G. Duda, E. di Tomaso, Y. Boucher, M. Ancukiewicz, D.V. Sahani, J. Lahdenranta, D.C. Chung, A.J. Fischman, G.Y. Lauwers, P. Shellito, B.G. Czito, T.Z. Wong, E. Paulson, M. Poleski, Z. Vujaskovic, R. Bentley, H.X. Chen, J.W. Clark, and R.K. Jain Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study J. Clin. Oncol. 27 2009 3020 3026
86. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, R.T. Tong, D.C. Chung, D.V. Sahani, S.P. Kalva, S.V. Kozin, M. Mino, K.S. Cohen, D.T. Scadden, A.C. Hartford, A.J. Fischman, J.W. Clark, D.P. Ryan, A.X. Zhu, L.S. Blaszkowsky, H.X. Chen, P.C. Shellito, G.Y. Lauwers, and R.K. Jain Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 2004 145 147 (Pubitemid 38524883)
87. C.G. Willett, Y. Boucher, D.G. Duda, E. di Tomaso, L.L. Munn, R.T. Tong, S.V. Kozin, L. Petit, R.K. Jain, D.C. Chung, D.V. Sahani, S.P. Kalva, K.S. Cohen, D.T. Scadden, A.J. Fischman, J.W. Clark, D.P. Ryan, A.X. Zhu, L.S. Blaszkowsky, P.C. Shellito, M. Mino-Kenudson, and G.Y. Lauwers Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J. Clin. Oncol. 23 2005 8136 8139 (Pubitemid 46657433)
88. R.K. Jain, D.G. Duda, J.W. Clark, and J.S. Loeffler Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat. Clin. Pract. Oncol. 3 2006 24 40 (Pubitemid 43108832)
89. R.S. Kerbel Tumor angiogenesis N. Engl. J. Med. 358 2008 2039 2049 (Pubitemid 351656458)
90. J. Hamzah, M. Jugold, F. Kiessling, P. Rigby, M. Manzur, H.H. Marti, T. Rabie, S. Kaden, H.J. Grone, G.J. Hammerling, B. Arnold, and R. Ganss Vascular normalization in Rgs5-deficient tumours promotes immune destruction Nature 453 2008 410 414 (Pubitemid 351693122)
91. W.S. Kamoun, C.D. Ley, C.T. Farrar, A.M. Duyverman, J. Lahdenranta, D.A. Lacorre, T.T. Batchelor, E. di Tomaso, D.G. Duda, L.L. Munn, D. Fukumura, A.G. Sorensen, and R.K. Jain Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J. Clin. Oncol. 27 2009 2542 2552
92. M. Relf, S. LeJeune, P.A. Scott, S. Fox, K. Smith, R. Leek, A. Moghaddam, R. Whitehouse, R. Bicknell, and A.L. Harris Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res. 57 1997 963 969 (Pubitemid 27098025)
93. H. Yoshiji, S.R. Harris, and U.P. Thorgeirsson Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells Cancer Res. 57 1997 3924 3928 (Pubitemid 27427677)
94. K. Li, Z. Sun, J. Zheng, Y. Lu, Y. Bian, M. Ye, X. Wang, Y. Nie, H. Zou, and D. Fan In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer J. Proteomics 82 2013 130 140
95. M. Klammer, M. Kaminski, A. Zedler, F. Oppermann, S. Blencke, S. Marx, S. Muller, A. Tebbe, K. Godl, and C. Schaab Phosphosignature predicts dasatinib response in non-small cell lung cancer Mol. Cell. Proteomics 11 2012 651 668
96. M.P. Alcolea, P. Casado, J.C. Rodriguez-Prados, B. Vanhaesebroeck, and P.R. Cutillas Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance Mol. Cell. Proteomics 11 2012 453 466
97. A.P. Trape, and A.M. Gonzalez-Angulo Breast cancer and metastasis: on the way toward individualized therapy Cancer Genomics Proteomics 9 2012 297 310
98. T.T. Batchelor, D.G. Duda, E. di Tomaso, M. Ancukiewicz, S.R. Plotkin, E. Gerstner, A.F. Eichler, J. Drappatz, F.H. Hochberg, T. Benner, D.N. Louis, K.S. Cohen, H. Chea, A. Exarhopoulos, J.S. Loeffler, M.A. Moses, P. Ivy, A.G. Sorensen, P.Y. Wen, and R.K. Jain Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J. Clin. Oncol. 28 2010 2817 2823
99. A.X. Zhu, D.V. Sahani, D.G. Duda, E. di Tomaso, M. Ancukiewicz, O.A. Catalano, V. Sindhwani, L.S. Blaszkowsky, S.S. Yoon, J. Lahdenranta, P. Bhargava, J. Meyerhardt, J.W. Clark, E.L. Kwak, A.F. Hezel, R. Miksad, T.A. Abrams, P.C. Enzinger, C.S. Fuchs, D.P. Ryan, and R.K. Jain Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J. Clin. Oncol. 27 2009 3027 3035
100. N. Azad, M. Yu, B. Davidson, P. Choyke, C.C. Chen, B.J. Wood, A. Venkatesan, R. Henning, K. Calvo, L. Minasian, D.C. Edelman, P. Meltzer, S.M. Steinberg, C.M. Annunziata, and E.C. Kohn Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort Mol. Cell. Proteomics 12 2013 1621 1631
101. M.R. Spitz, and M.L. Bondy The evolving discipline of molecular epidemiology of cancer Carcinogenesis 31 2010 127 134
102. D.D. Rosa, G. Ismael, L.D. Lago, and A. Awada Molecular-targeted therapies: lessons from years of clinical development Cancer Treat. Rev. 34 2008 61 80 (Pubitemid 351168606)
103. P. Warnault, A. Yasri, M. Coisy-Quivy, G. Cheve, C. Bories, B. Fauvel, and R. Benhida Recent advances in drug design of epidermal growth factor receptor inhibitors Curr. Med. Chem. 20 16 2013 2043 2067
104. S. Balabanov, T. Wilhelm, S. Venz, G. Keller, C. Scharf, H. Pospisil, M. Braig, C. Barett, C. Bokemeyer, R. Walther, T.H. Brummendorf, and A. Schuppert Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors PLoS One 8 2013 e53668